Recent Analysts’ Ratings Changes for KalVista Pharmaceuticals (KALV)

Several analysts have recently updated their ratings and price targets for KalVista Pharmaceuticals (NASDAQ: KALV):

• 5/1/2026 – KalVista Pharmaceuticals was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $27.00 price target on the stock, down from $37.00.
• 4/30/2026 – KalVista Pharmaceuticals was downgraded by JonesTrading from “strong-buy” to “hold”.
• 4/30/2026 – KalVista Pharmaceuticals was downgraded by Needham & Company LLC from “buy” to “hold”.
• 4/29/2026 – KalVista Pharmaceuticals was downgraded by Leerink Partners from “strong-buy” to “hold”.
• 4/29/2026 – KalVista Pharmaceuticals was downgraded by Citizens Jmp from “strong-buy” to “hold”.
• 4/21/2026 – KalVista Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/21/2026 – KalVista Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/13/2026 – KalVista Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/5/2026 – KalVista Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/28/2026 – KalVista Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/26/2026 – KalVista Pharmaceuticals had its price target raised by Stifel Nicolaus from $39.00 to $42.00. They now have a “buy” rating on the stock.
• 3/26/2026 – KalVista Pharmaceuticals had its price target lowered by Citizens Jmp from $29.00 to $28.00. They now have a “market outperform” rating on the stock.
• 3/25/2026 – KalVista Pharmaceuticals had its price target raised by Needham & Company LLC from $35.00 to $36.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total value of $2,960,232.75. Following the completion of the transaction, the insider directly owned 5,129,340 shares of the company’s stock, valued at approximately $86,942,313. This trade represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 10,034 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the transaction, the chief executive officer directly owned 442,883 shares of the company’s stock, valued at approximately $6,895,688.31. This trade represents a 2.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 263,937 shares of company stock valued at $4,572,251 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.